A5048398247- Bipolar Disorder and Treatment
- Mental Health and Psychiatry
- Schizophrenia research and treatment
- Electroconvulsive Therapy Studies
- Treatment of Major Depression
- Psychotherapy Techniques and Applications
- Obsessive-Compulsive Spectrum Disorders
- Psychosomatic Disorders and Their Treatments
- Attention Deficit Hyperactivity Disorder
- Personality Disorders and Psychopathology
- Mental Health Research Topics
- Child and Adolescent Psychosocial and Emotional Development
- Coordination Chemistry and Organometallics
- Health Systems, Economic Evaluations, Quality of Life
- Mental Health Treatment and Access
- Historical Psychiatry and Medical Practices
- Psychiatric care and mental health services
- Empathy and Medical Education
- Tryptophan and brain disorders
- Neurology and Historical Studies
- Adolescent and Pediatric Healthcare
- Health and Medical Research Impacts
- Stuttering Research and Treatment
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Pharmacological Effects and Toxicity Studies
Harvard University
2013-2024
Tufts University
2015-2024
Tufts Medical Center
2012-2023
Novartis (United States)
2018-2023
Grand Rapids Community College
2023
Harvard University Press
2023
Cambridge Health Alliance
2003-2021
Islamic Azad University, Babol
2021
Huangshan University
2020
Ghaem Hospital
2020
The risk-benefit profile of antidepressant medications in bipolar disorder is controversial. When conclusive evidence lacking, expert consensus can guide treatment decisions. International Society for Bipolar Disorders (ISBD) convened a task force to seek recommendations on the use antidepressants disorders.An iteratively developed through serial consensus-based revisions using Delphi method. Initial survey items were based systematic review literature. Subsequent surveys included new or...
Article AbstractObjectives: To determine if bipolar disorder isaccurately diagnosed in clinical practice and to assess theeffects of antidepressants on the course illness. Method: Charts outpatients with affectivedisorder diagnoses seen an outpatient clinic during 1 year (N= 85 or unipolar disorders) were reviewed. Pastdiagnostic treatment information was obtained by patientreport systematic psychiatric history. Bipolar diagnosis wasbased DSM-IV criteria using a SCID-based interview....
The study assessed the efficacy and safety of risperidone as an adjunctive agent to mood stabilizers in treatment acute mania.This 3-week randomized, double-blind, placebo-controlled included 156 bipolar disorder patients with a current manic or mixed episode who received stabilizer (lithium divalproex) placebo, risperidone, haloperidol. primary measure was Young Mania Rating Scale. Other assessments used Brief Psychiatric Scale, Clinical Global Impression scale, measures.The trial...
Few controlled studies have examined the use of atypical antipsychotic drugs for prevention relapse in patients with bipolar I disorder. Aims To evaluate whether olanzapine plus either lithium or valproate reduces rate relapse, compared alone.Patients achieving syndromic remission after 6 weeks'treatment (0.6-1.2 mmol/l) (50-125 microg/ml) received 5-20 mg/day (combination therapy) placebo (monotherapy), and were followed a double-masked trial 18 months.The treatment difference time to into...
OBJECTIVE: Antidepressant responses were compared in DSM-IV bipolar and unipolar depression. METHOD: The authors analyzed clinical records for outcomes of antidepressant trials 41 patients with depression 37 depression, similar age sex distribution. RESULTS: Short-term nonresponse was more frequent (51.3%) than (31.6%) Manic switching occurred only but happened less taking mood stabilizers (31.6% versus 84.2%). Cycle acceleration (25.6%), new rapid cycling 32.1%. Late response loss...
Practice guidelines have advised against treating patients with antidepressants during bipolar mixed states or dysphoric manias. However, few studies examined the outcomes of co-occurring manic and depressive symptoms who are treated plus mood stabilizing drugs.The authors compared in disorder received a agent versus without an antidepressant for episode accompanied by > = 2 concurrent symptoms. The 335 participants were drawn from first 2,000 enrollees National Institute Mental Health...
Article Abstract Objective: To assess long-term effectiveness and safety of randomized antidepressant discontinuation after acute recovery from bipolar depression. Method: In the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study, conducted between 2000 2007, 70 patients with DSM-IV-diagnosed disorder (72.5% non-rapid cycling, 70% type I) major depression, initially responding to treatment antidepressants plus mood stabilizers, euthymic 2 months, were openly...
Article AbstractBackground: Many patients with bipolar disorder receive multi-drug treatment regimens, but the distinguishing profiles of who complex pharmacologies have not been established.Method: Prescribing patterns lithium, anticonvulsants, antidepressants, and antipsychotics were examined for 4035 subjects (DSM-IV) immediately prior to entering Systematic Treatment Enhancement Program Bipolar Disorder (STEP-BD). Subjects recruited participation across 22 centers in United States...
This is the first book-length historical critique of psychiatry's mainstream ideology, biopsychosocial (BPS) model. Developed in twentieth century as an outgrowth psychosomatic medicine, model seen antidote to constraints medical psychiatry. Nassir Ghaemi details origins and evolution BPS explains how, where, why it fails live up its promises. He analyzes works founders, George Engel Roy Grinker Sr., traces rise acceptance, discusses relation thought William Osler Karl Jaspers. In assessing...
Inactive ingredients may not be inert Most drug formulations comprise mainly inactive known as excipients. Excipients are tested in animal studies and do display toxicity at allowed concentrations, but their interaction with molecular targets has been systematically explored. Pottel et al. examined excipient activity by combining large-scale computational screening targeted experimental testing. They identified 38 excipients activities against 44 targets. Several were active cell panels that...